Akebia Therapeutics (AKBA) Projected to Post Quarterly Earnings on Thursday

Akebia Therapeutics (NASDAQ:AKBA) is anticipated to release its earnings data before the market opens on Thursday, March 13th. Analysts expect Akebia Therapeutics to post earnings of ($0.05) per share and revenue of $37.36 million for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Akebia Therapeutics Trading Up 3.8 %

Shares of AKBA stock opened at $1.93 on Wednesday. Akebia Therapeutics has a 1 year low of $0.80 and a 1 year high of $2.48. The firm’s 50 day moving average is $2.02 and its 200-day moving average is $1.78. The firm has a market capitalization of $421.09 million, a price-to-earnings ratio of -8.39 and a beta of 0.94.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on AKBA shares. StockNews.com lowered shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, March 6th. HC Wainwright restated a “buy” rating and issued a $7.50 price objective on shares of Akebia Therapeutics in a report on Thursday, January 23rd.

Insider Activity at Akebia Therapeutics

In other Akebia Therapeutics news, CAO Richard C. Malabre sold 30,202 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $2.10, for a total value of $63,424.20. Following the sale, the chief accounting officer now directly owns 280,248 shares in the company, valued at approximately $588,520.80. This trade represents a 9.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO John P. Butler sold 144,250 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $2.10, for a total transaction of $302,925.00. Following the completion of the sale, the chief executive officer now owns 2,604,330 shares in the company, valued at approximately $5,469,093. This trade represents a 5.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 280,579 shares of company stock worth $589,216 over the last ninety days. Company insiders own 4.10% of the company’s stock.

About Akebia Therapeutics

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.